EarningsTempest posted EPS of ($3.16), which was better than both the analyst's estimate and the consensus estimate.
Partnership SupportRoche support provides crucial savings ahead of Phase 3, which could offset significant costs and validate amezalpat's potential in the 1L HCC treatment landscape.
Regulatory ProgressTempest recently held a successful EOP2 meeting with the FDA, reaching a broad agreement on the Phase 3 study plan, including dose schedule and primary endpoint.